Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for azd8055 (compound)
Most Correlated Studies
- Melanoma Me13 cells treated with MEK1/2, PI3K/mTOR, mTOR, and BRAF V600E inhibitors
- L1000 CMAP - Breast adenocarcinoma SKBR3 cells treated with small molecule perturbagens
- L1000 CMAP - Breast carcinoma BT20 cells treated with small molecule perturbagens
- L1000 CMAP - Prostate cancer LNCAP cells treated with small molecule perturbagens
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
Most Relevant Literature
- Anti-tumor effect of AZD8055 against bladder cancer and bladder cancer-associated macrophages.
- In Vitro and In Vivo Interactions of TOR Inhibitor AZD8055 and Azoles against Pathogenic Fungi.
- AZD8055 enhances in vivo efficacy of afatinib in chordomas.
- Comparison of dual mTORC1/2 inhibitor AZD8055 and mTORC1 inhibitor rapamycin on the metabolism of br…
- Activation of ERK and p38 Reduces AZD8055-Mediated Inhibition of Protein Synthesis in Hepatocellular…
Most Relevant Clinical Trials
- AZD8055 for Adults With Recurrent Gliomas
- Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055
- A Study of Tor Kinase Inhibitor in Advanced Tumors
- Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours
- Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Live…
